CAC Score and Medication-Driven Changes: What Women Need to Know About Coronary Calcium

What Is a CAC Score and Why Does It Matter Differently for Women?

A coronary artery calcium (CAC) score is a non-invasive CT-based measurement of calcified atherosclerotic plaque in the coronary arteries, expressed in Agatston units. It is the single strongest imaging predictor of future major adverse cardiovascular events (MACE) in asymptomatic adults. For women specifically, it resolves a problem that standard risk calculators do not: cardiovascular risk in women is systematically underestimated by tools built predominantly on male cohorts.

The MESA study (Multi-Ethnic Study of Atherosclerosis), which enrolled 6,814 participants including a substantial cohort of women, established sex-specific CAC percentile tables that are now the clinical standard for interpretation. Using a man's reference range on a woman's result is clinically incorrect.

Sex-Specific Physiology: Why Women's Scores Look Different

Women accumulate coronary calcium at a slower rate than men through the reproductive years, largely because estrogen suppresses vascular smooth muscle calcification. This changes sharply at menopause. Data from MESA show that CAC progression rates in women nearly double in the four years surrounding the final menstrual period, a window when circulating estradiol falls from roughly 100 pg/mL to below 20 pg/mL.

Because women's absolute scores are lower at every age, a CAC of 100 in a 55-year-old woman places her at a higher age- and sex-adjusted percentile than the same score in a 55-year-old man. The clinical implication is real: a 2018 analysis in JACC found that women with CAC scores in the 75th percentile or higher for their age and sex had cardiovascular event rates equivalent to men one decade older.

Across Reproductive Life Stages

Reproductive years (roughly ages 20-40). CAC scores above 0 in this group are unusual and should prompt aggressive risk-factor workup, including screening for familial hypercholesterolemia, lupus, and other inflammatory conditions that accelerate vascular aging in young women.

Perimenopause (roughly ages 45-55). This is the window of accelerated CAC progression. The SWAN Heart Study confirmed that the late perimenopause transition predicts CAC presence independently of traditional risk factors like LDL and blood pressure. Testing CAC during this window gives you a baseline that is actually meaningful.

Post-menopause. Absolute CAC scores rise faster here than in any other female life stage. CAC becomes the preferred tool to move women out of the intermediate-risk zone on the pooled cohort equations (PCE), where most women in their 50s and 60s cluster.

What Is the Normal Range and Optimal CAC Score for Women?

There is no single "normal" CAC score in the way a fasting glucose has a normal range. Instead, scores are interpreted against MESA age- and sex-specific percentile tables and in the context of each woman's overall risk profile.

The Four Clinical Tiers

| CAC Score | Clinical Interpretation for Women | |---|---| | 0 | No detectable calcified plaque. Very low 10-year MACE risk. | | 1-99 | Mild plaque burden. Lifestyle intervention; statin discussion, especially post-menopause. | | 100-299 | Moderate burden. Statin therapy generally warranted. | | ≥ 300 or ≥75th percentile | High burden. High-intensity statin; aspirin discussion; cardiology referral. |

A CAC of 0 is sometimes called the "warranty period" result. The 2019 ACC/AHA Guideline on Primary Prevention states that a CAC of 0 can be used to defer statin therapy in intermediate-risk patients who prefer to avoid medication, with a reassessment at 5-7 years. This is an explicit recommendation, not a vague suggestion.

What "Optimal" Actually Means

The word "optimal" in this context means a CAC of 0 with no progression on serial scanning. A score of 0 at age 50 predicts a 10-year MACE rate of roughly 2-3% in women, comparable to a 40-year-old with the same risk factor burden. A score above 100 at age 50 in a woman shifts her estimated 10-year risk above 7.5%, the threshold at which the 2019 ACC/AHA guidelines recommend initiating statin therapy.

There is no value in trying to achieve a specific CAC score through treatment. The score is a snapshot of plaque already deposited. The goal of therapy is to stop progression and reduce the lipid-rich, non-calcified component of plaque that actually ruptures, not to lower a number.

How Medications Change Your CAC Score

This is the area where the most clinical confusion exists, and where the research has matured significantly in the past decade.

Statins: The Paradox You Need to Understand

Statins are the best-studied drug class in relation to CAC scores. The finding is counterintuitive: statins can increase a CAC score by roughly 10-25% compared with placebo over 4-6 years of follow-up, even while reducing cardiovascular events by 25-35%.

The mechanism is not a sign of worsening disease. Statins accelerate calcification of existing soft, lipid-rich plaque into the dense, stable calcified form that the CT scanner picks up. Calcified plaque is less likely to rupture than its non-calcified precursor. The MESA statin-use substudy and the St. Francis Heart Study both documented this effect in women and men alike, with no sex-specific difference in the magnitude of the increase.

The clinical instruction this produces: If you are on a statin and your repeat CAC scan shows a higher score, do not interpret this as treatment failure. Share the result with your clinician in the context of your statin use. A moderate increase in a statin-treated patient is expected and does not indicate that the drug is working against you.

PCSK9 Inhibitors

Evolocumab and alirocumab reduce LDL by 50-60% on top of statin therapy. Early data from the FOURIER trial and its sub-studies suggest PCSK9 inhibitors may slow non-calcified plaque volume without the paradoxical calcification effect seen with statins. Dedicated CAC-specific imaging data in women from PCSK9 inhibitor trials remain limited. The FOURIER trial enrolled roughly 27% women, and sex-stratified CAC sub-studies have not been published as of mid-2025. This is a genuine evidence gap.

Hormone Therapy and CAC

This is one of the most practically relevant medication-CAC interactions for women approaching or past menopause.

The ELITE trial and the KEEPS trial (Kronos Early Estrogen Prevention Study) both used CAC as an outcome measure. KEEPS found that oral conjugated equine estrogen (0.45 mg/day) and transdermal estradiol (50 mcg/day) had similar CAC progression rates compared with placebo in recently menopausal women (mean time since menopause: 1.5 years). ELITE found a trend toward lower CAC progression with estradiol in women who started therapy within 6 years of menopause, supporting the timing hypothesis for cardiovascular benefit, though the CAC difference did not reach statistical significance.

A practical framework for interpreting this: hormone therapy initiated in early post-menopause (within 10 years of the final menstrual period and under age 60) appears neutral to mildly beneficial on CAC progression. Hormone therapy started more than 10 years after menopause should not be used with the expectation of CAC benefit and may be associated with accelerated calcification in women with pre-existing plaque.

Anti-Inflammatory Drugs

The CANTOS trial tested canakinumab, an interleukin-1 beta inhibitor, in patients with prior MI and elevated hsCRP. It reduced MACE by 15% independent of LDL lowering. CAC was not the primary endpoint, but mechanistically, targeting vascular inflammation should slow the progression of non-calcified plaque. This remains an area of active investigation, not established clinical practice for primary prevention in women.

Low-dose colchicine (0.5 mg daily) reduced MACE by 31% in the LoDoCo2 trial in patients with stable coronary artery disease. Sex-disaggregated CAC data from LoDoCo2 are not available, though the overall cardiovascular benefit was consistent across sexes.

GLP-1 Receptor Agonists

Semaglutide and liraglutide reduce cardiovascular events in people with type 2 diabetes and established CVD, as shown in SUSTAIN-6 and LEADER. Their effect on CAC specifically is not well characterized in women-only or primary-prevention cohorts. Body weight reduction of 10-15%, which GLP-1 agonists produce in women with obesity, lowers several CAC risk drivers including blood pressure, insulin resistance, and CRP. Whether this translates to measurable CAC progression slowing in women without established diabetes is being studied in ongoing trials.

Blood Pressure Medications

Hypertension is a stronger independent cardiovascular risk factor in women than in men. An analysis published in JACC in 2020 found that women with systolic blood pressure above 130 mmHg had a steeper CAC progression curve than men at the same systolic level. Antihypertensive therapy, particularly ACE inhibitors and ARBs, reduces vascular stiffness and may slow CAC progression, though direct CAC-specific randomized data are limited. The clinical priority remains achieving guideline-concordant blood pressure targets (below 130/80 mmHg per AHA 2017 guidelines) rather than treating a CAC number.

Who This Test Is Right For, by Life Stage and Condition

Women Who Benefit Most from CAC Testing

CAC testing adds the most information in women who fall into the intermediate-risk zone on the pooled cohort equations, a 10-year ASCVD risk of 7.5-20%. In this group, a CAC of 0 can defer statin therapy, and a CAC above 100 or above the 75th percentile for age and sex justifies starting it.

Specific groups where CAC meaningfully changes management include:

• Perimenopausal women with 1-2 traditional risk factors. The PCE underestimates risk in this group because it does not account for estrogen loss as an independent risk driver.
• Women with PCOS. Polycystic ovary syndrome is associated with accelerated CAC progression independent of BMI and insulin resistance, per a 2021 meta-analysis in Fertility and Sterility. Women with PCOS who reach their mid-40s without a CAC baseline are missing useful data.
• Women with a history of hypertensive disorders of pregnancy (HDP). Pre-eclampsia doubles lifetime cardiovascular risk. The AHA's 2021 call to action on maternal health recommends treating HDP history as a cardiovascular risk-enhancing factor, and CAC can help quantify that risk in the decade after delivery.
• Women with premature ovarian insufficiency (POI). Loss of ovarian function before age 40 is associated with a 50% higher cardiovascular mortality risk over a lifetime. CAC in a woman with POI in her late 30s or 40s provides actionable data.
• Women with lupus or rheumatoid arthritis. Systemic inflammation accelerates atherosclerosis. CAC is an appropriate tool for early risk stratification in this population, independent of traditional risk factors.

Women for Whom CAC Testing Adds Less

• Women with an established 10-year ASCVD risk above 20% already warrant statin therapy. CAC will not change that.
• Women under 40 without specific high-risk conditions. The pre-test probability of a meaningful score is very low.
• Women currently pregnant. See the section below.

Pregnancy, Lactation, and Contraception Considerations

CAC Scanning During Pregnancy: Avoid Unless Clinically Urgent

CAC scoring uses low-dose non-contrast CT, delivering approximately 1-3 mSv of radiation to the maternal chest. Fetal exposure from chest-level CT is very low, estimated at 0.01-0.1 mSv, well below the 50 mSv threshold associated with fetal harm per ACOG Committee Opinion 723. The dose is not the primary concern. The concern is clinical: elective cardiovascular risk stratification by CAC is a non-urgent procedure that can be deferred until the postpartum period without meaningful clinical harm in the vast majority of cases.

If a pregnant woman presents with acute chest pain and suspected coronary artery disease, CT coronary angiography rather than a CAC score would be the appropriate investigation, and the benefit-to-risk calculation changes entirely.

Lactation

CAC scoring does not involve contrast or radiotracer. There is no lactation safety concern from the scan itself. The question of whether to start or continue cardiac medications identified by a CAC-triggered workup, such as statins, is a separate issue.

Statins are contraindicated during breastfeeding. Statins transfer into breast milk and may interfere with infant cholesterol synthesis, which is critical for neurological development. The FDA prescribing information for all statins includes a warning against use during lactation. A woman who needs high-intensity statin therapy after a CAC-triggered workup should discuss feeding decisions with her clinician before initiating treatment.

Contraception and Cardiac Medications

Some medications started after a high CAC result carry contraception or pregnancy-planning implications:

• High-intensity statins (atorvastatin 40-80 mg, rosuvastatin 20-40 mg): Contraindicated in pregnancy (FDA pregnancy category X). Women of reproductive age starting a statin for CAC-indicated risk should use reliable contraception and have a preconception plan.
• ACE inhibitors and ARBs: Contraindicated in pregnancy. Women starting these for hypertension in the context of cardiovascular risk reduction need contraception and should transition to a pregnancy-compatible antihypertensive, such as labetalol or nifedipine, before attempting conception.
• Aspirin: Low-dose aspirin (81 mg) is actually recommended in women at high pre-eclampsia risk during pregnancy, but the indication and dose are distinct from cardiovascular primary prevention.

How to Track CAC Score Changes Over Time

A single CAC score is useful. Serial scans are more useful, and the interval that makes clinical sense is 3-5 years for women in the intermediate-risk zone, not annual scanning. Annual rescanning exposes you to unnecessary radiation without improving the actionable information you get.

What you are looking for on a repeat scan:

• Progression from 0 to any score. This is clinically meaningful and should trigger a statin discussion regardless of calculated risk.
• Rapid progression (more than 15% per year). This suggests a metabolic driver, such as uncontrolled LDL, poorly controlled blood pressure, or active inflammation, that warrants more aggressive workup.
• Stable score on statin therapy. Even a score that stays the same is a signal that plaque is not growing, which is the goal.

The MESA Progression Study found that annual CAC progression above 300 Agatston units per year was independently associated with increased MACE risk, even after adjusting for baseline score. This threshold has not been validated separately in women, which is an evidence gap worth naming.

Evidence Gaps: Where Women Are Underrepresented

Clinical trials informing CAC management have historically enrolled more men than women. The MESA study enrolled 53% women and is the strongest source of sex-specific data. FOURIER enrolled 27% women. LoDoCo2 enrolled 17% women. CANTOS enrolled 25% women.

What this means practically: most of the medication-CAC interaction data you read about was generated primarily in men and extrapolated to women. The direction of effect is probably similar, but the magnitude may differ. This honesty matters when your clinician is deciding whether a specific score crosses the threshold for treatment in your specific case.

The ACC/AHA 2019 Primary Prevention Guideline acknowledges sex as a risk-modifying factor and explicitly calls for sex-specific CAC percentile use, but it does not offer women-specific medication-CAC interaction guidance because the data do not yet exist in adequate volume.

Frequently Asked Questions